Skip to main content
. 2017 Sep 18;130(21):2243–2250. doi: 10.1182/blood-2017-07-793786

Table 3.

Sustained response rate, organ response, and response in multiple organs among patients who responded to ibrutinib

No. of responders Sustained response rate n (%)
Sustained response of ≥20 wk 28 20 (71)
Organ No. of responders with organ involvement at baseline Best ORR, n (%)
Skin 24 21 (88)
Mouth 24 21 (88)
Gastrointestinal 11 10 (91)
Organs showing response No. of patients with ≥2 involved organs at baseline among responders Best ORR, n (%)
≥2 organs 25 20 (80)